Show simple item record

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

dc.contributor.authorDirix, L. Y.en
dc.contributor.authorTonnesen, F.en
dc.contributor.authorCassidy, J.en
dc.contributor.authorEpelbaum, R.en
dc.contributor.authorHuinink, W. W. Ten Bokkelen
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorSorio, R.en
dc.contributor.authorGamucci, T.en
dc.contributor.authorWolff, I.en
dc.contributor.authorVelde, A. Teen
dc.contributor.authorLan, J.en
dc.contributor.authorVerweij, J.en
dc.creatorDirix, L. Y.en
dc.creatorTonnesen, F.en
dc.creatorCassidy, J.en
dc.creatorEpelbaum, R.en
dc.creatorHuinink, W. W. Ten Bokkelen
dc.creatorPavlidis, Nicholasen
dc.creatorSorio, R.en
dc.creatorGamucci, T.en
dc.creatorWolff, I.en
dc.creatorVelde, A. Teen
dc.creatorLan, J.en
dc.creatorVerweij, J.en
dc.date.accessioned2018-06-22T09:52:55Z
dc.date.available2018-06-22T09:52:55Z
dc.date.issued1996
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41569
dc.description.abstractIn a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.en
dc.language.isoengen
dc.sourceEuropean Journal of Cancer Part Aen
dc.subjectArticleen
dc.subjectAntineoplastic agentsen
dc.subjectHumanen
dc.subject80 and overen
dc.subjectAgeden
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast neoplasmsen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectPriority journalen
dc.subjectClinical trialen
dc.subjectMulticenter studyen
dc.subjectPhase 2 clinical trialen
dc.subjectAntineoplastic activityen
dc.subjectMaleen
dc.subjectIntravenous drug administrationen
dc.subjectVomitingen
dc.subjectFollow-up studiesen
dc.subjectGastric canceren
dc.subjectStomach neoplasmsen
dc.subjectBreast canceren
dc.subjectColorectal canceren
dc.subjectColorectal neoplasmsen
dc.subjectStomach canceren
dc.subjectNauseaen
dc.subjectPancreas canceren
dc.subject5 (1 aziridinyl) 3 hydroxymethyl 2 (3 hydroxy 1 propenyl) 1 methyl 4en
dc.subject7 indoledioneen
dc.subjectAziridinesen
dc.subjectDigestive system neoplasmsen
dc.subjectEo9en
dc.subjectIndolequinonesen
dc.subjectIndolesen
dc.subjectPancreatic canceren
dc.subjectPancreatic neoplasmsen
dc.subjectPhase ii studyen
dc.subjectProteinuriaen
dc.subjectRenal toxicityen
dc.titleEO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies groupen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/0959-8049(96)00226-2
dc.description.volume32
dc.description.issue11
dc.description.startingpage2019
dc.description.endingpage2022
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record